A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Breast Oncology

Phase

Division (Location)

Study ID

NCT#

Brief Description
A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.